Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip.

anti-PD-1 cancer models cancer-associated fibroblasts immuno-oncology immunotherapy lung cancer microfluidics patient-derived tumor microenvironment tumor-on-chip

Journal

Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894

Informations de publication

Date de publication:
27 Apr 2024
Historique:
received: 28 10 2023
revised: 29 02 2024
accepted: 10 04 2024
medline: 5 5 2024
pubmed: 5 5 2024
entrez: 4 5 2024
Statut: aheadofprint

Résumé

There is a compelling need for approaches to predict the efficacy of immunotherapy drugs. Tumor-on-chip technology exploits microfluidics to generate 3D cell co-cultures embedded in hydrogels that recapitulate simplified tumor ecosystems. Here, we present the development and validation of lung tumor-on-chip platforms to quickly and precisely measure ex vivo the effects of immune checkpoint inhibitors on T cell-mediated cancer cell death by exploiting the power of live imaging and advanced image analysis algorithms. The integration of autologous immunosuppressive FAP

Identifiants

DOI: 10.1016/j.xcrm.2024.101549 PMID: 38703767
pubmed: 38703767
pii: S2666-3791(24)00241-6
doi: 10.1016/j.xcrm.2024.101549
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101549

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests H.S. and I.V. are Roche employees. The STAMP method used in this work has been patented by I.V., A.M., E.M., and M.C.P.

Auteurs

Irina Veith (I)

Institut Curie, INSERM U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005 Paris, France; Institut Roche, 30 Cours de l'Île Seguin, 92100 Boulogne-Billancourt, France.

Martin Nurmik (M)

Institut Curie, INSERM U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005 Paris, France.

Arianna Mencattini (A)

Department of Electronic Engineering, University of Rome Tor Vergata, 00133 Rome, Italy.

Isabelle Damei (I)

INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine - Université Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.

Christine Lansche (C)

Institut Curie, INSERM U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005 Paris, France.

Solenn Brosseau (S)

Institut Curie, INSERM U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005 Paris, France; Université Paris Cité, Thoracic Oncology Department and CIC INSERM 1425, Hôpital Bichat-Claude Bernard, 75018 Paris, France.

Giacomo Gropplero (G)

Institut Curie, CNRS UMR168, Laboratoire Physico Chimie Curie, Institut Pierre-Gilles de Gennes, PSL Research University, 75005 Paris, France.

Stéphanie Corgnac (S)

INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine - Université Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.

Joanna Filippi (J)

Department of Electronic Engineering, University of Rome Tor Vergata, 00133 Rome, Italy.

Nicolas Poté (N)

Université Paris Cité, INSERM UMR1152, Hôpital Bichat-Claude Bernard, 75018 Paris, France; Department of Pathology, Hôpital Bichat-Claude Bernard, 75018 Paris, France.

Edouard Guenzi (E)

Université Paris Cité, INSERM UMR1152, Hôpital Bichat-Claude Bernard, 75018 Paris, France; Department of Pathology, Hôpital Bichat-Claude Bernard, 75018 Paris, France.

Anaïs Chassac (A)

Department of Pathology, Hôpital Bichat-Claude Bernard, 75018 Paris, France.

Pierre Mordant (P)

Université Paris Cité, Thoracic Surgery Department, Hôpital Bichat-Claude Bernard, 75018 Paris, France.

Jimena Tosello (J)

INSERM U932, PSL Research University, Institut Curie Research Center, Paris, France; Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France.

Christine Sedlik (C)

INSERM U932, PSL Research University, Institut Curie Research Center, Paris, France; Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France.

Eliane Piaggio (E)

INSERM U932, PSL Research University, Institut Curie Research Center, Paris, France; Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France.

Nicolas Girard (N)

INSERM U932, PSL Research University, Institut Curie Research Center, Paris, France; Institut Curie, Institut du Thorax Curie Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, France.

Jacques Camonis (J)

Institut Curie, INSERM U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005 Paris, France.

Hamasseh Shirvani (H)

Institut Roche, 30 Cours de l'Île Seguin, 92100 Boulogne-Billancourt, France.

Fathia Mami-Chouaib (F)

INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine - Université Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France.

Fatima Mechta-Grigoriou (F)

Institut Curie, INSERM U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005 Paris, France.

Stéphanie Descroix (S)

Institut Curie, CNRS UMR168, Laboratoire Physico Chimie Curie, Institut Pierre-Gilles de Gennes, PSL Research University, 75005 Paris, France.

Eugenio Martinelli (E)

Department of Electronic Engineering, University of Rome Tor Vergata, 00133 Rome, Italy.

Gérard Zalcman (G)

Institut Curie, INSERM U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005 Paris, France; Université Paris Cité, Thoracic Oncology Department and CIC INSERM 1425, Hôpital Bichat-Claude Bernard, 75018 Paris, France. Electronic address: gerard.zalcman@aphp.fr.

Maria Carla Parrini (MC)

Institut Curie, INSERM U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005 Paris, France. Electronic address: maria-carla.parrini@curie.fr.

Classifications MeSH